Pharmacologic Treatment of Behavioral and Psychological Symptoms of Dementia in Nursing Homes: Update of the 2008 JAMDA Recommendations

Journal of the American Medical Directors Association

Volumn 16, Issue 6, 2015, Pages 527-532

  Anguish, Isabelle ^a   Locca, Jean François ^a   Büla, Christophe ^b   Zumbach, Serge ^c   Bugnon, Olivier ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c Psychiatric Hospital   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; MELATONIN; QUETIAPINE; TRAZODONE;

AGITATION; DEMENTIA; DEPRESSION; HUMAN; LETTER; NURSING HOME; NURSING HOME PATIENT; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; SLEEP DISORDER; SYSTEMATIC REVIEW (TOPIC); ALGORITHM; HOME FOR THE AGED; MENTAL DISORDERS; PRACTICE GUIDELINE; PSYCHOLOGY;

ALGORITHMS; DEMENTIA; HOMES FOR THE AGED; HUMANS; MENTAL DISORDERS; NURSING HOMES; PRACTICE GUIDELINES AS TOPIC;

EID: 84929963577     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2015.03.014     Document Type: Letter

References (14)

1. Locca J.F., Bula C.J., Zumbach S., Bugnon O. Pharmacological treatment of behavioral and psychological symptoms of dementia (BPSD) in nursing homes: Development of practice recommendations in a Swiss canton. JAm Med Dir Assoc 2008, 9:439-448.
2. Jansen S.L., Forbes D., Duncan V., et al. Melatonin for the treatment of dementia. Cochrane Database Syst Rev 2006, 1:CD003802.
3. Maglione M., Ruelaz Maher A., Hu J., et al. Off-Label Use of Atypical Antipsychotics: An Update. Comparative Effectiveness review No. 43. (Prepared by the Southern California Evidence-based Practice Center under Contract No. HHSA290-2007-10062-1) 2011, Agency for Healthcare Research and Quality, Rockville, MD.
4. National Institute for Health and Clinical Excellence: Guidance. Dementia: A NICE-SCIE Guideline on Supporting People With Dementia and Their Carers in Health and Social Care 2007, National Collaborating Center for Mental Health, The British Psychological Society and The Royal College of Psychiatrists, Leicester (UK), Review decision date: April 2012.
5. Kirchner V., Kelly C.A., Harvey R.J. Thioridazine for dementia. Cochrane Database Syst Rev 2001, 4:CD000464.
6. Lonergan E., Luxenberg J., Colford J. Haloperidol for agitation in dementia. Cochrane Database Syst Rev 2002, 2:CD002852.
7. Lonergan E., Luxenberg J. Valproate preparations for agitation in dementia. Cochrane Database Syst Rev 2009, 3:CD003945.
8. Martinon-Torres G., Fioravanti M., Grimley E.J. Trazodone for agitation in dementia. Cochrane Database Syst Rev 2004, 4:CD004990.
9. Sorbi S., Hort J., Erkinjuntti T., et al. EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia. Eur J Neurol 2012, 19:1159-1179.
10. Oertel W.H., Berardelli A., Bloem B.R., et al. Late (complicated) Parkinson's disease. European Handbook of Neurological Management 2011, Vol 1:237-267. Wiley-Blackwell, Oxford, UK. 2nd ed.
11. Diagnosis and pharmacological management of Parkinson's disease. A national clinical guideline 2010, Scottish Intercollegiate Guidelines Network (SIGN), Scottish Intercollegiate Guidelines Network (SIGN), Edinburgh (Scotland).
12. Seitz D.P., Adunuri N., Gill S.S., et al. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev 2011, 2:CD008191.
13. Declercq T., Petrovic M., Azermai M., et al. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev 2013, 3:CD007726.
14. McCleery J., Cohen D.A., Sharpley A.L. Pharmacotherapies for sleep disturbances in Alzheimer's disease. Cochrane Database Syst Rev 2014, 3:CD009178.